| pathology | treatment | patient | Demonstrated benefit and harm | k | | | |
|---|
| diabetes type 2 | mitiglinide | not classified | versus No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Gao | mitiglinide 10 - 20 mg three times daily (n=291) vs. nateglinide 120 mg three times daily (n=0) | Chinese type 2 diabetes mellitus patients | double-blind Parallel groups Sample size: 291/0 Primary endpoint: FU duration: 20 weeks | | Kaku, 2009 | additional mitiglinide 5 or 10 mg tid (n=-9) vs. placebo on top pioglitazone (n=-9) | Japanese type 2 diabetic patients who are insufficiently controlled by pioglitazone monotherapy | multicenter Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 16 weeks | | Kumashiro, 2007 | mitiglinide (n=-9) vs. on top of once daily insulin glargine (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
| diabetes type 2 | nateglinide | not classified | versus No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | | | T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Li, 2009 | Nateglinide (n=-9) vs. repaglinide (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Li, 2007 | nateglinide 90 mg three times daily (n=115) vs. repaglinide 1.0 mg three times daily (n=115) | Chinese patients with type 2 diabetes | Parallel groups Sample size: 115/115 Primary endpoint: FU duration: 12 weeks |
|
| diabetes type 2 | nateglinide | not classified | versus placebo or control No demonstrated result for efficacy | 9 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Marre, 2002 | nateglinide 60 mg, 120 mg before three meals (n=-9) vs. placebo (n=-9) | metformin-treated patients with HbA1c between 6.8% and 11% | double-blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: | | Horton, 2000 | 120 mg nateglinide before meals (n=179) vs. placebo (n=172) | patients with an HbA1c level between 6.8 and 11.0% during a 4-week placebo run-in | double-blind Parallel groups Sample size: 179/172 Primary endpoint: FU duration: | | Hanefeld, 1990 | nateglinide at doses of 30 mg, 60 mg, 120 mg, or 180 mg (n=229) vs. placebo (n=60) | | double-blind Parallel groups Sample size: 229/60 Primary endpoint: FU duration: 12 weeks | | Saloranta, 2002 | nateglinide (30, 60, or 120 mg, with meals). (n=675) vs. placebo (n=0) | patients with type 2 diabetes but only moderately elevated fasting plasma glucose (FPG = 7.0-8.3 mmol/liter) | double-blind Parallel groups Sample size: 675/0 Primary endpoint: FU duration: 24 weeks | | Mari, 2005 | 30, 60, or 120 mg nateglinide (n=108) vs. placebo (n=0) | mild type 2 diabetic men and women (fasting glucose 7.0-8.3 mmol/l) on diet treatment | double_blind Parallel groups Sample size: 108/0 Primary endpoint: FU duration: 24 weeks | | Goldberg, 1998 | repaglinide (n=66) vs. placebo (n=33) | type 2 diabetes | double-blind Parallel groups Sample size: 66/33 Primary endpoint: FU duration: | | Jovanovic, 2000 | repaglinide 1 mg or repaglinide 4 mg (n=286) vs. placebo (n=75) | | double-blind Parallel groups Sample size: 286/75 Primary endpoint: FU duration: 24 weeks | | Bech, 2003 | repaglinide initiated at 0.5 mg per meal, increased to 1 mg after 4 weeks if fasting plasma glucose exceeded 7.8 mmol/l. (n=253) vs. placebo (n=0) | pharmacotherapy-naive patients with Type 2 diabetes | double-blind Parallel groups Sample size: 253/0 Primary endpoint: FU duration: 16 weeks | | Moses, 2001 | 0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks depending on blood glucose response) (n=408) vs. placebo (n=0) | patients with type 2 diabetes considered poorly controlled by diet, but without a history of previous antidiabetic medication | double-blind Parallel groups Sample size: 408/0 Primary endpoint: FU duration: 16 weeks |
|
| diabetes type 2 | nateglinide | not classified | versus active treatment No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Ristic, 2006 | nateglinide plus metformin (n=133) vs. gliclazide plus metformin (n=129) | Patients with inadequate glucose control on maximal doses of metformin | double-blind Parallel groups Sample size: 133/129 Primary endpoint: FU duration: 24 weeks |
|
| diabetes type 2 | repaglinide | not classified | versus No demonstrated result for efficacy | 9 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Lund, 2007 | repaglinide 2 mg thrice daily (n=-9) vs. metformin 1 g twice daily (n=-9) | non-obese patients with type 2 diabetes | double-blind Cross over Sample size: -9/-9 Primary endpoint: FU duration: | | Landgraf, 1999 | repaglinide, administered preprandially three times daily (n=-9) vs. glibenclamide, given preprandially once or twice daily (n=-9) | | double-blind Sample size: -9/-9 Primary endpoint: FU duration: 14 weeks | | Marbury, 1999 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Wolffenbuttel, 1999 | repaglinide (0.5-4 mg t.i.d.) (n=211) vs. glyburide (1.75-10.5 mg daily) (n=109) | | double-blind Sample size: 211/109 Primary endpoint: FU duration: 1 year | | Madsbad, 2001 | repaglinide, 1-4 mg at mealtimes (n=256) vs. glipizide, 5-15 mg daily (n=0) | | double-blind Sample size: 256/0 Primary endpoint: FU duration: 1 year | | Raskin, 2000 | repaglinide (0.5–4.0 mg at meals), (n=256) vs. combination of repaglinide (1–4 mg at meals) and troglitazone (200–600 mg once
daily) (n=0) | Patients with type 2 diabetes who
had inadequate glycemic control (HbA1c 7.0%) during previous monotherapy | open Sample size: 256/0 Primary endpoint: FU duration: 22 weeks | | Raskin, 2001 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Raskin, 2001 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Landin-Olsson, 1999 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
| diabetes type 2 | repaglinide | not classified | versus placebo or control No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | | | T1 vs T0 | | | |
| Trial | Treatments | Patients | Method |
|---|
| Moses, 1999 | prestudy dose of metformin with the addition of repaglinide (n=27) vs. prestudy dose of metformin (n=27) | patients with type 2 diabetes who had inadequate glycemic control (HbA1c > 7.1%) when receiving the antidiabetic agent metformin | open Parallel groups Sample size: 27/27 Primary endpoint: FU duration: 12 weeks | | Chuang, 1999 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Goldberg, 1998 | repaglinide (n=66) vs. placebo (n=33) | patients with type 2 diabetes | double-blind Parallel groups Sample size: 66/33 Primary endpoint: FU duration: 18 weeks | | Jovanovic, 2000 | repaglinide 1 mg (n = 140), or repaglinide 4 mg (n = 146) (n=286) vs. placebo (n=75) | | double-blind Sample size: 286/75 Primary endpoint: FU duration: 24 weeks |
|
